Author

Maria Elzbieta Sheean

Observed names: Kolanczyk, Maria Elzbieta, Maria E Sheean, Maria E. Kolanczyk, Maria E. Sheean, Maria Sheean

Observed institutions: European Medicines Agency, Helmholtz Association of German Research Centres, Max Delbrück Center, Center for Regenerative Therapies Dresden, Biotechnologisches Zentrum, University of Bari Aldo Moro, Technische Universität Dresden

ORCID: 0000-0003-3055-0495

Observed ORCID: 0000-0003-3055-0495

OpenAlex ID: A5042921765

The Transcription Factor c-Maf Controls Touch Receptor Development and Function

2012 · Hagen Wende, Stefan G. Lechner, et al. · Science · 175

Duplication of fgfr1 Permits Fgf Signaling to Serve as a Target for Selection during Domestication

2009 · Nicolas Rohner, Miklós Bercsényi, et al. · Current Biology · 127

PDF

Activation of MAPK overrides the termination of myelin growth and replaces Nrg1/ErbB3 signals during Schwann cell development and myelination

2014 · Maria E. Sheean, Erik McShane, et al. · Genes & Development · 103

PDF

Neuregulin 3 promotes excitatory synapse formation on hippocampal interneurons

2018 · Thomas Müller, Stephanie Braud, et al. · The EMBO Journal · 83

PDF

Demonstrating significant benefit of orphan medicines: analysis of 15 years of experience in Europe

2017 · Laura Fregonese, Lesley Greene, et al. · Drug Discovery Today · 28

Regulatory Standards in Orphan Medicinal Product Designation in the EU

2021 · Stelios Tsigkos, Segundo Mariz, et al. · Frontiers in Medicine · 18

PDF

Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions

2017 · Maria E. Sheean, Violeta Stoyanova-Beninska, et al. · Drug Discovery Today · 17

Defining orphan conditions in the context of the European orphan regulation: challenges and evolution

2018 · Daniel J. O’Connor, Maria E. Sheean, et al. · Nature Reviews Drug Discovery · 13

Establishing rarity in the context of orphan medicinal product designation in the European Union

2017 · Stelios Tsigkos, Matthias Philipp Hofer, et al. · Drug Discovery Today · 13

Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases

2019 · Maria E. Sheean, Eva Malikova, et al. · Drug Discovery Today · 10

PDF

Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit–The EU Regulator's Perspective

2021 · Maria E. Sheean, Frauke Naumann-Winter, et al. · Frontiers in Medicine · 5

PDF

227th ENMC International Workshop:

2017 · Raffaella Willmann, Filippo Buccella, et al. · Neuromuscular Disorders · 5

From guideline to practice: three years of ICH S11 insights and recommendations

2025 · Diana Tavares, Hsiao-Tzu Chien, et al. · Frontiers in Medicine · 3

PDF

Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.

2023 · Joan Busner, Gahan Pandina, et al. · PubMed Central · 1

PDF

Signaling mechanisms and developmental function of fibroblast growth factor receptors in zebrafish

2009 · Kolanczyk, Maria Elzbieta · Qucosa (Saxon State and University Library Dresden) · 1

PDF

Translating non-clinical proof-of-concept data into paediatric development decisions: the case of HER2-targeting antibody-drug conjugates

2026 · Pauliina Lehtolainen-Dalkilic, Caoimhin G. Concannon, et al. · EJC Paediatric Oncology

PDF

Integrating non-clinical and clinical evidence for prioritisation in paediatric oncology drug development: Regulatory experience with three PARP inhibitors

2026 · Karen Van Malderen, Sofie Peirs, et al. · EJC Paediatric Oncology

PDF

Works count: 17

Citation count: 602

H-index: 10

I10-index: 10